miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect

Sun,Yan; Zhao,Xiaoping; Zhou,Yuhong; Hu,Yu

doi:10.3892/or.2012.1958

miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect

Authors:
- Yan Sun
- Xiaoping Zhao
- Yuhong Zhou
- Yu Hu
View Affiliations

Affiliations: Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China, Department of Biochemistry and Molecular Biology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200011, P.R. China, Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
Published online on: August 8, 2012 https://doi.org/10.3892/or.2012.1958
Pages: 1346-1352

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer represents one of the most challenging diseases. Increasing evidence indicates that aberrant expression of microRNAs (miRNAs) is related to pathogenesis of colorectal cancer. Cancer cells reprogram metabolic pathways to sustain higher proliferation rates. Whether mechanisms underlying the role of miRNA in colorectal cancer are involved in metabolic reprogramming and the mechanisms through which miRNAs alter cancer metabolism are as yet unknown. Herein, we show that miR-124, miR-137 and miR-340 are associated with poor prognosis of colorectal cancer. Expression of these miRNAs inhibits the growth of colorectal cancer cells. PKM (pyruvate kinase isozyme) alternative splicing proteins (PTB1/hnRNAPA1/hnRNAPA2), which control the inclusion of exon 9 (PKM1) or exon 10 (PKM2), are targeted by miR-124, miR-137 and miR-340. Consequently, miR-124, miR-137 and miR-340 switch PKM gene expression from PKM2 to PKM1. High ratios of PKM1/PKM2 inhibit the glycolysis rate, but elevate the glucose flux into oxidative phosphorylation. These results demonstrate that miRNAs (miR-124, miR-137 and miR-340) impair colorectal cancer growth by counteracting the Warburg effect due to regulating alternative splicing of the PKM gene.

View Figures

View References

1	American Cancer Society. NY: Global Cancer Facts & Figures. 2nd edition. http://www.cancer.org/Research/CancerFactsFigures/GlobalCancerFactsFigures/index. Accessed 2008
2	Malafosse R, Penna C, Sa Cunha A and Nordlinger B: Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol. 12:887–894. 2001. View Article : Google Scholar : PubMed/NCBI
3	Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
4	Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar
5	Schetter AJ, Leung SY, Sohn JJ, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436. 2008. View Article : Google Scholar : PubMed/NCBI
6	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
7	Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004. View Article : Google Scholar : PubMed/NCBI
8	Jones RG and Thompson CB: Tumor suppressors and cell metabolism: a recipe for cancer growth. Gene Dev. 23:537–548. 2009. View Article : Google Scholar : PubMed/NCBI
9	Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI
10	Mazurek S, Boschek CB, Hugo F and Eigenbrodt E: Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 15:300–308. 2005. View Article : Google Scholar : PubMed/NCBI
11	Noguchi T, Inoue H and Tanaka T: The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J Biol Chem. 261:13807–13812. 1986.PubMed/NCBI
12	Christofk HR, Vander Heiden MG, Wu N, Asara JM and Cantley LC: Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 452:181–186. 2008. View Article : Google Scholar : PubMed/NCBI
13	Vander Heiden MG, Locasale JW, Swanson KD, et al: Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science. 329:1492–1499. 2010.PubMed/NCBI
14	Christofk HR, Vander Heiden MG, Harris MH, et al: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 452:230–233. 2008. View Article : Google Scholar : PubMed/NCBI
15	David CJ, Chen M, Assanah M, Canoll P and Manley JL: HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 463:364–368. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wang BD, Kline CL, Pastor DM, et al: Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Mol Cancer. 9:982010. View Article : Google Scholar : PubMed/NCBI
17	Patnaik SK, Kannisto E, Knudsen S and Yendamuri S: Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 70:36–45. 2010. View Article : Google Scholar : PubMed/NCBI
18	Silber J, Lim DA, Petritsch C, et al: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 6:142008. View Article : Google Scholar : PubMed/NCBI
19	Vanderweele DJ and Rudin CM: Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate. Mol Cancer Res. 3:635–644. 2005. View Article : Google Scholar
20	Chen M, Zhang J and Manley JL: Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res. 70:8977–8980. 2010. View Article : Google Scholar : PubMed/NCBI
21	Zhang J, Guo H, Qian G, et al: MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network. Mol Cancer. 9:2112010. View Article : Google Scholar : PubMed/NCBI
22	Akao Y, Nakagawa Y, Hirata I, et al: Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther. 17:398–408. 2010. View Article : Google Scholar : PubMed/NCBI
23	Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A and Lund AH: MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One. 5:e88362010. View Article : Google Scholar : PubMed/NCBI
24	Kaelin WG Jr and Thompson CB: Q&A: Cancer: clues from cell metabolism. Nature. 465:562–564. 2010.
25	Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH and Thompson CB: Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol. 21:5899–5912. 2001.PubMed/NCBI
26	Ashcroft SJ, Weerasinghe LC, Bassett JM and Randle PJ: The pentose cycle and insulin release in mouse pancreatic islets. Biochem J. 126:525–532. 1972.PubMed/NCBI
27	Center MM, Jemal A, Smith RA and Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin. 59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
28	Makeyev EV, Zhang J, Carrasco MA and Maniatis T: The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell. 27:435–448. 2007. View Article : Google Scholar : PubMed/NCBI
29	Smith P, Al Hashimi A, Girard J, Delay C and Hebert SS: In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs. J Neurochem. 116:240–247. 2011. View Article : Google Scholar : PubMed/NCBI
30	Werner JM, Eger K and Jurgen Steinfelder H: Comparison of the rapid pro-apoptotic effect of trans-beta-nitrostyrenes with delayed apoptosis induced by the standard agent 5-fluorouracil in colon cancer cells. Apoptosis. 12:235–246. 2007. View Article : Google Scholar
31	Luo W, Hu H, Chang R, et al: Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 145:732–744. 2011. View Article : Google Scholar : PubMed/NCBI